Company ReNeuron Group Plc London S.E.
Equities
Biotechnology & Medical Research
Business Summary
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell-based Therapies
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +31.51% |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom, United States, China and South East Asia
74.3
%
| 0 | 70.5 % | 0 | 74.3 % | +38.73% |
United States
25.7
%
| 0 | 29.5 % | 0 | 25.7 % | +14.29% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Suzanne Hancock
COO | Chief Operating Officer | - | 16-12-31 |
Chief Tech/Sci/R&D Officer | - | 22-03-02 | |
Simon Dew
PRN | Corporate Officer/Principal | - | 22-10-31 |
Shaun Stapleton
LAW | General Counsel | - | 15-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Walton
BRD | Director/Board Member | 61 | 22-03-21 |
Iain Ross
CHM | Chairman | 71 | 21-06-30 |
Director/Board Member | 61 | 21-07-13 | |
Michael Owen
BRD | Director/Board Member | 73 | 15-12-03 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 57,173,760 | 44,745,727 ( 78.26 %) | 0 | 78.26 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+17.96% | 47.02B | |
+48.77% | 41.86B | |
+1.17% | 41.76B | |
-4.27% | 28.8B | |
+11.42% | 26.05B | |
-21.39% | 19.15B | |
+4.86% | 12.55B | |
+27.29% | 12.34B | |
-3.50% | 11.82B |